Technology evaluation: ChimeriVax-DEN, Acambis/Aventis

Curr Opin Mol Ther. 2004 Aug;6(4):443-50.

Abstract

Acambis, in collaboration with Aventis Pasteur, is developing a chimeric vaccine based on a recombinant yellow fever vaccine for the potential prevention of dengue virus infection. The vaccine is undergoing phase I clinical trials.

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Child
  • Clinical Trials, Phase I as Topic
  • Dengue / prevention & control*
  • Dengue Virus / genetics*
  • Dengue Virus / immunology*
  • Dengue Virus / pathogenicity
  • Drug Evaluation, Preclinical
  • Humans
  • Severe Dengue / prevention & control*
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / toxicity
  • Viral Vaccines* / adverse effects
  • Viral Vaccines* / therapeutic use
  • Viral Vaccines* / toxicity
  • West Nile Virus Vaccines

Substances

  • Antibodies, Viral
  • ChimeriVax
  • Vaccines, Synthetic
  • Viral Vaccines
  • West Nile Virus Vaccines